FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
3 April 2018 07:00 GMT US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMABPASUDOTOX IN HAIRY CELL LEUKAEMIA Moxetumomab pasudotox BLA granted Priority Review AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an investigational anti-CD22 recombinant immunotoxin and a potential new medicine for the treatment of adult patients with hairy cell leukaemia (HCL) who have received at least two prior lines of